• Search Funds
  • Model Portfolios
  • Provider
  • Sector
  • Manager

Search by provider name

Search by sector name

Search by manager name

Search by Risk Level

AXA Framlington Biotech Fund Z Acc

  • Fund Info & charges
  • Performance
  • Fund breakdown
  • Dividend History
Fund Provider AXA IM
Fund Summary The aim of this Fund is to provide long-term capital growth.
SEDOL code B784NS1
ISIN GB00B784NS11
Fund code FMBTA
Managers Linden Thomson, Dani Saurymper
Manager Tenure 7 years
Morningstar Category Sector Equity Biotechnology
IMA Sector Specialist
Fund Size £414 million
Fund Type OEIC
Management Style Active
Total Expense Ratio (TER) 0.82%
Cavendish ongoing charge 0.05%
FundsNetwork Service Fee 0.20%
Minimum Initial Investment £25
Minimum Top Up £25
Minimum Monthly Investment £25
Sell Price £3.395
Buy Price £3.395
Price Change -1.1357%
Price Date 20th May 2019
Yield Currently unavailable
Dividend Frequency Semi-Annually
ISA Eligible Yes
SIPP Eligible Yes
Inception Date 27th November 2001
Fund Status OPEN

3-year Mean Monthly Return: 1.014%

Annual Returns 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009
Fund Performance +10.45% +0.38% +30.53% -26.70% +74.29% +33.86% +34.90% +23.36% -2.59% +17.04%
Benchmark Performance
(Sector Equity Biotechnology)
+8.90% +1.02% +31.51% -25.58% +66.15%
Time Period Cumulative Benchmark Performance
(Sector Equity Biotechnology)
Fund Compared to Benchmark
1 day -1.14% +0.81% -1.95%
1 week 1.86% +1.72% +0.14%
1 month 1.34% -0.68% +2.03%
3 months -2.75% -3.04% +0.29%
6 months 4.88% +3.41% +1.47%
1 year 0.98% +2.27% -1.29%
3 years 41.75% +36.27% +5.48%
5 years 84.99% +76.49% +8.50%
10 years 402.44% +335.66% +66.77%
YTD 14.08% +13.05% +1.03%
Since inception 299.79% Currently unavailable Currently unavailable

Top 10 shares for this fund

Share Name Country Value
Alexion Pharmaceuticals Inc USA 7.42%
Gilead Sciences Inc USA 6.80%
Celgene Corp USA 5.91%
Biogen Inc USA 5.70%
Regeneron Pharmaceuticals Inc USA 4.58%
Amgen Inc USA 4.55%
Takeda Pharmaceutical Co Ltd JPN 3.18%
Biomarin Pharmaceutical Inc USA 3.16%
Vertex Pharmaceuticals Inc USA 2.97%
Ionis Pharmaceuticals Inc USA 2.72%

Currently unavailable